TIM‐3 expression induces resistance to PD‐1 inhibitor in G‐CSF‐producing lung spindle cell carcinoma: A case report

G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation

(2021) Ioannis Karagiannidis et al.   CYTOKINE

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma

(2020) Charlotte Domblides et al.   Journal of Thoracic Oncology

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

(2019) Bo Gong et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients

(2018) Kunlatida Maneenil et al.   Clinical Lung Cancer

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

(2017) Suzanne George et al.   IMMUNITY

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling

(2017) Alexa B. Schrock et al.   Journal of Thoracic Oncology

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma

(2013) Thibault Vieira et al.   Journal of Thoracic Oncology

Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells

(2010) V. Dardalhon et al.   JOURNAL OF IMMUNOLOGY